药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02268 药明合联

未开盘 11-18 16:08:08

23.750

-1.200

-4.81%

最高25.000	最低23.150	成交量455.62万
今开24.450	昨收24.950	日振幅7.41%
总市值284.79亿	流通市值284.79亿	总股本11.99亿
成交额1.09亿	换手率0.38%	流通股本11.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02268","market":"HK","secType":"STK","nameCN":"药明合联","latestPrice":23.75,"timestamp":1731917288016,"preClose":24.95,"halted":0,"volume":4556174,"delay":0,"floatShares":1199107777,"shares":1199107777,"eps":0.29846698,"marketStatus":"未开盘","marketStatusCode":0,"change":-1.2,"latestTime":"11-18 16:08:08","open":24.45,"high":25,"low":23.15,"amount":109125081,"amplitude":0.074148,"askPrice":23.9,"askSize":9000,"bidPrice":23.75,"bidSize":4500,"shortable":3,"etf":0,"ttmEps":0.5297860554980424,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1731979800000},"adr":0,"listingDate":1700150400000,"adjPreClose":24.95,"openAndCloseTimeList":[[1731893400000,1731902400000],[1731906000000,1731916800000]],"volumeRatio":0.6668880174070032,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02268/tweets","defaultTab":"tweets","newsList":[{"id":"2484619314","title":"开源证券医药行业2025年度投资策略：长期产业趋势未曾改变 关注板块企稳回升","url":"https://stock-news.laohu8.com/highlight/detail?id=2484619314","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484619314?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:04","pubTimestamp":1731913467,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，开源证券发布研报称，医药长期产业趋势未曾改变，板块有望企稳回升。开源证券主要观点如下：长期产业趋势未曾改变，板块有望企稳回升2024年前三季度，医药板块整体收入增速-1.72%，归母净利润增速-5.50%；单看Q3，2024Q3医药板块整体收入增速-1.27%、归母净利润增速-16.03%，行业经营表现整体承压，随着三季度开始院端基数因素缓解，老龄化刚需+创新供给有望拉动板块恢复稳健增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212169.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161027","02268","BK1141","SG9999014674.SGD"],"gpt_icon":0},{"id":"2484974236","title":"药明合联(02268)下跌5.01%，报23.7元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484974236","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484974236?lang=zh_cn&edition=full","pubTime":"2024-11-18 13:29","pubTimestamp":1731907747,"startTime":"0","endTime":"0","summary":"11月18日，药明合联(02268)盘中下跌5.01%，截至13:29，报23.7元/股，成交6173.17万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2024年中报，药明合联营业总收入16.65亿元、净利润4.88亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/18132945390915.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","SG9999014674.SGD","02268"],"gpt_icon":0},{"id":"2483842737","title":"药明合联11月14日主力资金流入139万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2483842737","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483842737?lang=zh_cn&edition=full","pubTime":"2024-11-14 16:15","pubTimestamp":1731572157,"startTime":"0","endTime":"0","summary":"11月14日, 药明合联股价跌5.16%，报收24.80元，成交金额1.07亿元，换手率0.35%，振幅8.99%，量比0.28。药明合联今日主力资金净流入139万元，连续5日净流入，上一交易日主力净流入285万元，今日环比减少51.23%。近一年数据显示，该股主力连续5日净流入后，次日上涨概率为83.33%，平均涨幅为2.34%。该股近5个交易日下跌2.72%，主力资金累计净流入2984万元；近20日主力资金累计净流入4994万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114161630abc04f69&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114161630abc04f69&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02268","BK1141","SG9999014674.SGD"],"gpt_icon":0},{"id":"2483131018","title":"药明合联(02268)下跌5.07%，报25.3元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483131018","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483131018?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:06","pubTimestamp":1731463606,"startTime":"0","endTime":"0","summary":"11月13日，药明合联(02268)盘中下跌5.07%，截至10:06，报25.3元/股，成交2275.8万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2024年中报，药明合联营业总收入16.65亿元、净利润4.88亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/13100645230950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02268","SG9999014674.SGD","BK1141"],"gpt_icon":0},{"id":"2483092424","title":"药明合联11月12日获南向资金加仓191.80万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483092424","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483092424?lang=zh_cn&edition=full","pubTime":"2024-11-13 09:30","pubTimestamp":1731461415,"startTime":"0","endTime":"0","summary":"11月12日, 南向资金增持药明合联191.80万股。截止当日收盘，港股通共持有药明合联10449.21万股，占流通股8.70%。港股通增持金额前五个股分别为中芯国际、建设银行、中升控股、安踏体育、中国神华。药明合联近5个交易日上涨14.38%，港股通累计增持249.90万股；近20个交易日上涨16.89%，港股通累计增持715.55万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113093203a231f136&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113093203a231f136&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02268","BK1141","SG9999014674.SGD"],"gpt_icon":0},{"id":"2482253724","title":"药明合联11月12日主力资金流入555万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2482253724","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482253724?lang=zh_cn&edition=full","pubTime":"2024-11-12 16:16","pubTimestamp":1731399401,"startTime":"0","endTime":"0","summary":"11月12日, 药明合联股价涨7.46%，报收26.65元，成交金额4.40亿元，换手率1.36%，振幅17.14%，量比1.22。药明合联今日主力资金净流入555万元，连续3日净流入，上一交易日主力净流入1930万元，今日环比减少71.24%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为57.14%，平均涨幅为2.62%。该股近5个交易日上涨14.59%，主力资金累计净流入2779万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入3328万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112161849a22fab80&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112161849a22fab80&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02268","SG9999014674.SGD","BK1141"],"gpt_icon":0},{"id":"1126465172","title":"异动解读 | 药明合联股价大涨逾14% CRO行业复苏预期受青睐","url":"https://stock-news.laohu8.com/highlight/detail?id=1126465172","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126465172?lang=zh_cn&edition=full","pubTime":"2024-11-12 10:50","pubTimestamp":1731379854,"startTime":"0","endTime":"0","summary":"药明合联(02268)今日盘中大涨14.92%,引发市场关注。消息面上,CRO概念股整体呈现上涨态势,机构看好CRO行业未来业绩复苏前景。\n\n据报道,尽管2024年中报期间,CRO公司业绩端仍存在一定压力,但部分公司订单已开始恢复,订单复苏趋势持续性较强。订单改善初步体现出行业景气度回暖,后续将逐步转化到业绩端,CRO公司业绩复苏值得期待。\n\n另一方面,在新一轮降息周期和新产品周期的利好下,行业需求有望逐步回暖。同时降低药物研发成本的诉求也有望推动CRO公司获得更多订单,药明合联凭借其成本和效率优势在同行中更具竞争力。总体而言,行业复苏预期成为助推药明合联股价大涨的主因。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02268"],"gpt_icon":0},{"id":"2482371526","title":"港股异动 | CRO概念股涨幅居前 机构称未来业绩复苏值得期待 赴美上市创新药存在研发降成本诉求","url":"https://stock-news.laohu8.com/highlight/detail?id=2482371526","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482371526?lang=zh_cn&edition=full","pubTime":"2024-11-12 10:38","pubTimestamp":1731379109,"startTime":"0","endTime":"0","summary":"兴业证券指出，CXO板块尽管2024年中报多数公司业绩端仍有一定压力，但部分公司订单已开始出现恢复，结合三季报情况当前订单复苏趋势显示出持续性。订单改善初步体现出行业景气度复苏，后续将逐步转化到业绩端，CXO未来业绩复苏值得期待。降药价将增加赴美上市创新药研发的降成本诉求，有利于具有成本、效率优势的国内CXO公司，建议关注药明康德、康龙化成、凯莱英等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1242518931.SGD","02268","LU2125910500.SGD","LU2045819591.USD","BK1141","LU0979878070.USD","BK1610","IE00B0JY6N72.USD","BK1574","02269","LU0856984785.SGD","LU0359201612.USD","LU1720050803.USD","LU0348735423.USD","LU0307460666.USD","LU1046422090.SGD","LU0456827905.SGD","SG9999002463.SGD","LU1242518857.USD","LU0456846285.SGD","03347","LU0348825331.USD","LU2242644610.SGD","LU0417516738.SGD","LU0823426480.USD","LU0516423091.SGD","BK1589","LU0823426308.USD","LU0052750758.USD","LU0359202008.SGD","BK1521","LU0043850808.USD","SG9999002562.SGD","159992","LU0417516902.SGD","LU0819121731.USD","02359","LU0516422366.SGD","LU0516423174.USD","LU2039709279.SGD","LU0708995583.HKD","06978","LU0588546209.SGD","SG9999014674.SGD","LU1880383366.USD","BK1583","LU0181495838.USD","LU0140636845.USD","LU0051755006.USD","LU0327786744.USD"],"gpt_icon":0},{"id":"2482970317","title":"药明合联(02268)上涨5.24%，报26.1元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2482970317","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482970317?lang=zh_cn&edition=full","pubTime":"2024-11-12 09:47","pubTimestamp":1731376041,"startTime":"0","endTime":"0","summary":"11月12日，药明合联(02268)盘中上涨5.24%，截至09:47，报26.1元/股，成交3351.13万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2024年中报，药明合联营业总收入16.65亿元、净利润4.88亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/12094745179034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SG9999014674.SGD","BK1141","02268"],"gpt_icon":0},{"id":"2482271291","title":"药明合联11月11日获主力加仓1930万元 环比增加2543.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482271291","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482271291?lang=zh_cn&edition=full","pubTime":"2024-11-11 16:15","pubTimestamp":1731312942,"startTime":"0","endTime":"0","summary":"11月11日, 药明合联股价跌2.17%，报收24.80元，成交金额1.35亿元，换手率0.45%，振幅2.96%，量比0.41。药明合联今日主力资金净流入1930万元，上一交易日主力净流入73万元，今日环比增加2543.84%。该股近5个交易日上涨9.65%，主力资金累计净流入2114万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入2364万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111161557abb55b4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111161557abb55b4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02268","BK1141","SG9999014674.SGD"],"gpt_icon":0},{"id":"2482227667","title":"药明合联(02268)出现大手买入61.3万股，成交价$25.25，涉资1.548千万","url":"https://stock-news.laohu8.com/highlight/detail?id=2482227667","media":"阿斯达克财经","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482227667?lang=zh_cn&edition=full","pubTime":"2024-11-11 14:35","pubTimestamp":1731306900,"startTime":"0","endTime":"0","summary":"[大手成交]药明合联(02268)在下午02:35出现大手买入，成交量为61.3万，成交价为港币$25.25，涉资1.548千万。至目前为止，股价跌1.775%，今日最高价为$25.45，而最低价为$24.7，总成交量为465.35万股，总成交金额港币$1.166亿。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145554547_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145554547_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2411117315/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02268","BK1141","SG9999014674.SGD"],"gpt_icon":0},{"id":"2482356212","title":"【券商聚焦】交银国际认为特朗普当选后国内CXO海外业务前景喜忧参半","url":"https://stock-news.laohu8.com/highlight/detail?id=2482356212","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482356212?lang=zh_cn&edition=full","pubTime":"2024-11-11 09:06","pubTimestamp":1731287213,"startTime":"0","endTime":"0","summary":"整体来看，该行对于第二届特朗普政府下的中国CXO前景持谨慎乐观态度，继续推荐细分赛道景气度相对较高的药明合联和金斯瑞生物。对于创新药，该行认为关税加征的影响可能十分有限，后续重点关注跨境交易的政策变化。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/ZWZlMGNjODY1NzQ4NjMzODA5NjU5ODM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZWZlMGNjODY1NzQ4NjMzODA5NjU5ODM=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947429","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","01548","03329","HK0000306701.USD","02268","HK0000320264.USD","BK1583","SG9999014674.SGD","HK0000306685.HKD","CXO","HK0000320223.HKD","BK1576","BK1147"],"gpt_icon":0},{"id":"2481902031","title":"药明合联赢得2024 World ADC大奖，蝉联\"最佳CDMO冠军\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2481902031","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481902031?lang=zh_cn&edition=full","pubTime":"2024-11-08 11:50","pubTimestamp":1731037800,"startTime":"0","endTime":"0","summary":"中国上海和美国圣地亚哥2024年11月8日 /美通社/ -- 全球领先的专注于提供抗体偶联药物等生物偶联药物端到端CRDMO服务的药明合联，近日在2024 World ADC奖评选中荣膺\"最佳 CDMO冠军\"，这是公司连续第二年荣获该项殊荣。此外，公司已连续三年在World ADC奖中斩获多项荣誉，包括2022年\"最佳CMO亚军\"以及2023年\"最佳CDMO冠军\"。本届World ADC大会上，药明合联还获得了\"最佳CRO\"和\"最佳ADC平台技术\"的提名。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4551571_ZH51571_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","ADC","CDMO","SG9999014674.SGD","BK4231","BK4080","BK1141","02268"],"gpt_icon":0},{"id":"2481169974","title":"南向资金11月7日净卖出药明合联39.30万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2481169974","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481169974?lang=zh_cn&edition=full","pubTime":"2024-11-08 09:30","pubTimestamp":1731029416,"startTime":"0","endTime":"0","summary":"11月7日，南向资金减持药明合联39.30万股连续3日减持。截止当日收盘，港股通共持有药明合联10145.01万股，占流通股8.44%。药明合联近5个交易日上涨11.26%，港股通累计减持26.40万股；近20个交易日上涨13.97%，港股通累计增持987.81万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108093215a22221b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108093215a22221b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999014674.SGD","BK1141","02268"],"gpt_icon":0},{"id":"2481910931","title":"【券商聚焦】国信证券维持药明合联(02268)“优于大市”评级 料公司未来3年业务将保持较快增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2481910931","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481910931?lang=zh_cn&edition=full","pubTime":"2024-11-07 13:12","pubTimestamp":1730956359,"startTime":"0","endTime":"0","summary":"2021-2023年公司三年营收复合增速180.4%、归母净利润复合增速120.9%。该行指，根据药明合联招股说明书，预计2030年ADC市场规模将增长至647亿美元。综合能力领先，多重优势打造六大核心竞争力：1）多项顶级技术加该行表示，维持“优于大市”评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/NDM0MmU4OTRhMjU2ZjIzMGMyNTgwMjU0NDY3MDU0NTg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NDM0MmU4OTRhMjU2ZjIzMGMyNTgwMjU0NDY3MDU0NTg=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947281","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268","002736"],"gpt_icon":0},{"id":"2481130119","title":"药明合联(02268)上涨5.14%，报25.55元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2481130119","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481130119?lang=zh_cn&edition=full","pubTime":"2024-11-07 11:02","pubTimestamp":1730948572,"startTime":"0","endTime":"0","summary":"11月7日，药明合联(02268)盘中上涨5.14%，截至11:02，报25.55元/股，成交5512.39万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2024年中报，药明合联营业总收入16.65亿元、净利润4.88亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/07110245024594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02268","BK1141","SG9999014674.SGD"],"gpt_icon":0},{"id":"2481692390","title":"港股药明系走高，药明合联(02268.HK)涨7%，药明康德(02359.HK)涨近6%，药明生物(02269.HK)涨超3%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2481692390","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481692390?lang=zh_cn&edition=full","pubTime":"2024-11-06 10:41","pubTimestamp":1730860907,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0348735423.USD","LU0823426308.USD","BK1141","07226","LU1242518931.SGD","LU1242518857.USD","LU0823426480.USD","BK1589","LU1997245094.SGD","LU0359201612.USD","LU0856984785.SGD","LU0051755006.USD","LU2125910500.SGD","LU0039217434.USD","LU2242644610.SGD","LU2039709279.SGD","IE00B0JY6N72.USD","BK1521","LU1688375341.USD","LU0516423091.SGD","LU2488822045.USD","LU0572944931.SGD","LU0043850808.USD","LU0181495838.USD","LU0326950275.SGD","LU0417516738.SGD","BK1576","LU0327786744.USD","LU0516422366.SGD","LU0456842615.SGD","LU0588546209.SGD","LU1997245177.USD","HSCEI","YANG","BK1610","LU0456827905.SGD","LU0516422952.EUR","LU2045819591.USD","LU0359202008.SGD","SG9999002463.SGD","LU0516422440.USD","LU0348825331.USD","LU0979878070.USD","603259","LU0320764599.SGD","HSTECH","LU0052750758.USD","02269","02268","02359"],"gpt_icon":0},{"id":"2481911126","title":"药明合联(02268)上涨5.36%，报24.55元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2481911126","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481911126?lang=zh_cn&edition=full","pubTime":"2024-11-06 10:16","pubTimestamp":1730859409,"startTime":"0","endTime":"0","summary":"11月6日，药明合联(02268)盘中上涨5.36%，截至10:16，报24.55元/股，成交4959.22万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2024年中报，药明合联营业总收入16.65亿元、净利润4.88亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/06101644978472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SG9999014674.SGD","02268","BK1141"],"gpt_icon":0},{"id":"2481610772","title":"药明合联：抗体偶联药物CRDMO龙头企业 一体化平台赋能药物生产开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2481610772","media":"国信证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481610772?lang=zh_cn&edition=full","pubTime":"2024-11-06 00:00","pubTimestamp":1730822400,"startTime":"0","endTime":"0","summary":"公司为全球抗体偶联药物CRDMO 龙头企业。药明合联为全球领先的抗体偶联药物合同研究、开发及生产组织，为客户提供全流程端到端服务，赋能药物生产开发全过程，综合能力领先。根据药明合联招股说明书，预计2030年ADC 市场规模将增长至647 亿美元。由于生物偶联药物开发的高难度性，ADC 外包率居高不下，预计到2030 年，全球ADC 及更广泛生物偶联药物的外包服务市场规模将扩张至110 亿美元，ADC 外包服务公司大有可为。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110613261895bdd7ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110613261895bdd7ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02268","BK1141","SG9999014674.SGD"],"gpt_icon":0},{"id":"2478603117","title":"南向资金10月25日净买入药明合联19.85万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2478603117","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478603117?lang=zh_cn&edition=full","pubTime":"2024-10-28 09:30","pubTimestamp":1730079017,"startTime":"0","endTime":"0","summary":"10月25日, 南向资金增持药明合联19.85万股，连续3日增持。截止当日收盘，港股通共持有药明合联9907.16万股，占流通股8.25%。药明合联近5个交易日下跌0.43%，港股通累计增持166.30万股；近20个交易日上涨18.64%，港股通累计增持1769.22万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028093234ab7991d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028093234ab7991d8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","SG9999014674.SGD","02268"],"gpt_icon":0}],"profile":{"websiteUrl":"http://wuxixdc.com","stockEarnings":[{"period":"1week","weight":-0.0423},{"period":"1month","weight":0.015},{"period":"3month","weight":0.2007},{"period":"6month","weight":0.4956},{"period":"1year","weight":-0.1518},{"period":"ytd","weight":-0.2578}],"compareEarnings":[{"period":"1week","weight":-0.0416},{"period":"1month","weight":-0.059},{"period":"3month","weight":0.118},{"period":"6month","weight":0.0198},{"period":"1year","weight":0.1216},{"period":"ytd","weight":0.1484}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"WuXi XDC Cayman Inc是一家主要从事提供抗体偶联药物（ADC）及更广泛生物偶联药物的合同研究、开发和生产服务（CRDMO）的控股公司。该公司通过两个分部开展其业务。按有偿服务基准的研究服务分部透过有偿服务合约向客户提供研究服务。按全时当量基准提供的研究服务分部提供一个项目小组，该小组的员工在特定时间内专门负责客户的研究。基于生物药和小分子药物，该公司还提供跨领域的综合服务，涵盖生物偶联药物及连接子及有效载荷的发现、工艺开发及药品生产质量管理规范（GMP）生产。该公司在国内外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.222222,"avgChangeRate":0.010265},{"month":2,"riseRate":0.666667,"avgChangeRate":0.058284},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.010372},{"month":4,"riseRate":0.555556,"avgChangeRate":0.03555},{"month":5,"riseRate":0.333333,"avgChangeRate":0.006014},{"month":6,"riseRate":0.4,"avgChangeRate":-0.032735},{"month":7,"riseRate":0.4,"avgChangeRate":0.011785},{"month":8,"riseRate":0.4,"avgChangeRate":-0.114063},{"month":9,"riseRate":0.333333,"avgChangeRate":0.019767},{"month":10,"riseRate":0.777778,"avgChangeRate":0.151657},{"month":11,"riseRate":0.333333,"avgChangeRate":0.008796},{"month":12,"riseRate":0.111111,"avgChangeRate":-0.068876}],"exchange":"SEHK","name":"药明合联","nameEN":"WUXI XDC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明合联,02268,药明合联股票,药明合联股票老虎,药明合联股票老虎国际,药明合联行情,药明合联股票行情,药明合联股价,药明合联股市,药明合联股票价格,药明合联股票交易,药明合联股票购买,药明合联股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}